Exact Sciences (EXAS) Tops Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts EXAS Hot Sheet
Join SI Premium – FREE
Exact Sciences (NASDAQ: EXAS) reported Q2 EPS of ($0.46), $0.09 better than the analyst estimate of ($0.55). Revenue for the quarter came in at $21.2 million versus the consensus estimate of $18.54 million.
For earnings history and earnings-related data on Exact Sciences (EXAS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nurix Therapeutics, Inc. (NRIX) Reports Q3 EPS of $4.73
- StubHub Holdings (STUB) PT Lowered to $11 at Goldman Sachs
- Artisan Partners Asset Management (APAM) PT Lowered at TD Cowen After 'Another Attrition-Driven Miss'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
